TY - JOUR
T1 - Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
AU - Schmitt, Manfred
AU - Mengele, Karin
AU - Napieralski, Rudolf
AU - Magdolen, Viktor
AU - Reuning, Ute
AU - Gkazepis, Apostolos
AU - Sweep, Fred
AU - Brünner, Nils
AU - Foekens, John
AU - Harbeck, Nadia
PY - 2010/11
Y1 - 2010/11
N2 - The prognostic and/or predictive value of the cancer biomarkers, urokinase-type plasminogen activator (uPA) and its inhibitor (plasminogen activator inhibitor [PAI]-1), determined by ELISA in tumor-tissue extracts, was demonstrated for several cancer types in numerous clinically relevant retrospective or prospective studies, including a multicenter breast cancer therapy trial (Chemo-N0). Consequently, for the first time ever for any cancer biomarker for breast cancer, uPA and PAI-1 have reached the highest level of evidence, level-of-evidence-1. At present, two other breast cancer therapy trials, NNBC-3 and Plan B, also incorporating uPA and PAI-1 as treatment-assignment tools are in effect. Furthermore, small synthetic molecules targeting uPA are currently in Phase II clinical trials in patients afflicted with advanced cancer of the ovary, breast or pancreas.
AB - The prognostic and/or predictive value of the cancer biomarkers, urokinase-type plasminogen activator (uPA) and its inhibitor (plasminogen activator inhibitor [PAI]-1), determined by ELISA in tumor-tissue extracts, was demonstrated for several cancer types in numerous clinically relevant retrospective or prospective studies, including a multicenter breast cancer therapy trial (Chemo-N0). Consequently, for the first time ever for any cancer biomarker for breast cancer, uPA and PAI-1 have reached the highest level of evidence, level-of-evidence-1. At present, two other breast cancer therapy trials, NNBC-3 and Plan B, also incorporating uPA and PAI-1 as treatment-assignment tools are in effect. Furthermore, small synthetic molecules targeting uPA are currently in Phase II clinical trials in patients afflicted with advanced cancer of the ovary, breast or pancreas.
KW - clinical utility
KW - individualized tailored cancer care
KW - personalized cancer treatment
KW - predictive impact
KW - prognostic relevance
KW - prospective clinical trial
KW - retrospective clinical study
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=78649277216&partnerID=8YFLogxK
U2 - 10.1586/erm.10.71
DO - 10.1586/erm.10.71
M3 - Review article
C2 - 21080821
AN - SCOPUS:78649277216
SN - 1473-7159
VL - 10
SP - 1051
EP - 1067
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
IS - 8
ER -
